[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350224-105":59,"doc-detail-350224-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","theranostics-2026-vol-16-issue-11-integrated-radio-theranostics-using-a-89zrzr-177-lulu-labeled-b7-h3-antibody-drug-conjugate-for-prostate-cancer","Theranostics 2026 - Vol. 16 - Issue 11 - Integrated radio-theranostics using a [89Zr]Zr-/[177 Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancer","","Prostate cancer remains a leading cause of cancer-related mortality in men, and current PSMA-directed theranostics face limitations from heterogeneous target expression and therapy-induced downregulation. A B7-H3 (CD276)-targeted antibody-drug conjugate was developed as an integrated theranostic platform, using [89Zr]Zr for immunoPET imaging and [177 Lu]Lu for radionuclide therapy. The study evaluates binding specificity, tumor targeting, biodistribution, dosimetry, therapeutic efficacy, and safety in prostate cancer xenograft models.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/theranostics-2026-vol-16-issue-11-integrated-radio-theranostics-using-a-89zrzr-177-lulu-labeled-b7-h3-antibody-drug-conjugate-for-prostate-cancer/350224/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/theranostics-2026-vol-16-issue-11-integrated-radio-theranostics-using-a-89zrzr-177-lulu-labeled-b7-h3-antibody-drug-conjugate-for-prostate-cancer/350224.png","ImageObject",300,407,{"name":92,"@type":93},"นรินทร์","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",22,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why was B7-H3 selected as a theranostic target for prostate cancer?","Question",{"text":113,"@type":114},"B7-H3 is highly and stably expressed in prostate cancer and remains present in primary and metastatic lesions even under therapeutic intervention, addressing limitations of PSMA heterogeneity and downregulation.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What radionuclides were used for imaging and therapy in this integrated approach?",{"text":118,"@type":114},"The antibody-drug conjugate was radiolabeled with [89Zr]Zr for immunoPET imaging and [177 Lu]Lu for radionuclide therapy.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the [177 Lu]Lu-B7-H3 ADC perform compared with other treatment strategies?",{"text":122,"@type":114},"It produced marked tumor growth inhibition and a survival benefit, outperforming radiolabeled antibody, ADC monotherapy, and sequential treatment strategies, with reversible transient hematological changes and no additional organ toxicity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350224,1790185744,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},2336475104957,"https://ap-avatar.wpscdn.com/avatar/22000c4c6bd8a5076e1?x-image-process=image/resize,m_fixed,w_180,h_180&k=1787554080175789136","Theranostics 2026, Vol. 16, Issue 11 6132  \nIvyspring  \nInternational Publisher  \nTheranostics  \n2026; 16(11): 6132-6144. doi: 10.7150/thno.125878  \nResearch Paper  \nIntegrated radio-theranostics using a [89Zr]Zr-/[177 Lu] Lu-labeled B7-H3 antibody-drug conjugate for prostate cancer  \nYongkang Qiu1\\#, Tingfei Gu1\\#, Tianyao Wang1\\#, Yelin Mulati2, Xinyao Sun1, Qi Yang1, Lele Song1, Tingting Yuan1, Yu Fan2􀀍, Lei Kang1􀀍, Weibo Cai3􀀍  \n1. Department of Nuclear Medicine, Peking University First Hospital, Beijing 100034, China.  \n2. Department of Urology, Institute of Urology, Peking University First Hospital, Peking University, The National Urological Cancer Center of China, Beijing 100034, China.  \n3. Departments of Radiology and Medical Physics, University of Wisconsin-Madison, Madison, WI 53705, USA.  \n\\# These authors contributed equally.  \n􀀍 Corresponding authors: Weibo Cai, Departments of Radiology and Medical Physics, University of Wisconsin - Madison, Madison, WI 53705, USA. [WCai@uwhealth.org](WCai@uwhealth.org); Lei Kang, Department of Nuclear Medicine, Peking University First Hospital, No. 8 Xishiku Str., Xicheng Dist, Beijing, 100034, China. E-mail: [kanglei@bjmu.edu.cn](kanglei@bjmu.edu.cn); Yu Fan, Department of Urology, Institute of Urology, Peking University First Hospital, Peking University, The National Urological Cancer Center of China, Beijing, 100034, [China. dantefanbmu@pku.edu.cn](China. dantefanbmu@pku.edu.cn).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [https://ivyspring.com/terms](https://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2025.09.26; Accepted: 2026.04.03; Published: 2026.04.16  \nAbstract  \n\n| Rationale: Prostate cancer remains a leading cause of cancer-related mortality in men. Although PSMA-directed theranostics have achieved clinical success, heterogeneous expression and therapy-induced downregulation limit their broad applicability. B7-H3 (CD276), which is highly and stably expressed in prostate cancer, represents a promising alternative theranostic target.\u003Cbr>Methods: A B7-H3 targeted antibody-drug conjugate (ADC) was radiolabeled with [89Zr]Zr-for immunoPET imaging and [177 Lu]Lu for radionuclide therapy. In vitro binding specificity, in vivo tumor targeting, biodistribution, therapeutic efficacy, dosimetry, and safety were systematically assessed in prostate cancer xenograft models, with comparisons to radiolabeled antibody, ADC monotherapy, sequential therapy, and vehicle controls.\u003Cbr>Results: Histological analysis in prostate cancer patients suggested B7-H3 was consistently and highly expressed in primary and metastatic lesions and remained stable under therapeutic intervention. [89Zr]Zr-B7-H3 ADC immunoPET imaging demonstrated high and specific tumor uptake (33.2 ± 1.0 %ID/g at 144 h) and favorable tumor-to-background ratios. Therapeutic studies revealed that [177 Lu]Lu-B7-H3 ADC achieved marked tumor growth inhibition and survival benefit, with comparable efficacy even if reduced the dose of ADC in the treatment system. Integrated [177Lu]Lu-ADC therapy outperformed radiolabeled antibody, ADC monotherapy, and sequential treatment strategies. No additional organ toxicity was observed compared with ADC alone, and transient hematological changes following [177 Lu]Lu administration were reversible.\u003Cbr>Conclusions: The [89Zr]Zr-/[177 Lu]Lu-B7-H3 ADC theranostic platform enables accurate imaging, precise tumor targeting, and enhanced antitumor efficacy at reduced ADC doses without increasing systemic toxicity, supporting its translational potential for prostate cancer. |  |\n| --- | --- |\n| Keywords: B7-H3; Prostate cancer; Theranostics; Radioligand therapy; Antibody-drug conjugate\u003Cbr>Introduction |  |\n| Prostate cancer remains a leading cause of cancer-related mortality in men worldwide, with dise","cbCailRp4DgJuoUM","https://ap.wps.com/l/cbCailRp4DgJuoUM","pdf",7773424,13,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusions\n# Keywords and Introduction\n## Keywords\n## Introduction","[{\"question\":\"Why was B7-H3 selected as a theranostic target for prostate cancer?\",\"answer\":\"B7-H3 is highly and stably expressed in prostate cancer and remains present in primary and metastatic lesions even under therapeutic intervention, addressing limitations of PSMA heterogeneity and downregulation.\"},{\"question\":\"What radionuclides were used for imaging and therapy in this integrated approach?\",\"answer\":\"The antibody-drug conjugate was radiolabeled with [89Zr]Zr for immunoPET imaging and [177 Lu]Lu for radionuclide therapy.\"},{\"question\":\"How did the [177 Lu]Lu-B7-H3 ADC perform compared with other treatment strategies?\",\"answer\":\"It produced marked tumor growth inhibition and a survival benefit, outperforming radiolabeled antibody, ADC monotherapy, and sequential treatment strategies, with reversible transient hematological changes and no additional organ toxicity.\"}]","Theranostics 2026 - Vol. 16 - Issue 11 - Integrated radio-theranostics using a [89Zr]Zr-/[177 Lu]Lu-labeled B7-H3 antibody-drug conjugate for prostate cancer | PDF",1790087912,33,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6fd0e9925bfb04d9f6c114715041818e.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8b2e1de1f952bd071557f98fca758e00.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e8a6d35b78d5101216942631b545dfd3.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3be759599a8394e266ec421b08e5a22.webp",980,1268]